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Abstract 
The human leukocyte antigen class I (HLA-I) genes shape our immune response against 
pathogens and cancer. Certain HLA-I variants can bind a much wider range of peptides 
than others, a feature that could be favorable against a range of viral diseases. However, 
the implications of this phenomenon on cancer immune response is unknown. In this 
paper, we quantified peptide repertoire breadth (or promiscuity) of a representative set 
of HLA-I alleles, and found that cancer patients that carry HLA-I alleles with high peptide 
binding promiscuity are characterized by significantly worse prognosis after immune 
checkpoint inhibitor treatment. This trend can be explained by a reduced capacity of 
promiscuous HLA-I molecules to discriminate between human self and tumour peptides, 
yielding a shift in regulation of T-cells in the tumour microenvironment from activation 
to tolerance. In summary, HLA-I peptide binding specificity shapes neopeptide 
immunogenicity and the self-immunopeptidome repertoire in an antagonistic manner. It 
could also underlie a negative trade-off between antitumour immunity and the genetic 
susceptibility to viral infections.  
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Introduction 
HLA-I molecules generally reside on the surface of human nucleated cells, and present 
intracellularly derived peptides. HLA-I genes are the most variable genes in the human 
genome1, and this variation shapes susceptibility to infectious diseases, autoimmune 
disorders and cancers1. 
The adaptive immune recognition of mutated peptides (neopeptides) is essential for an 
effective tumor destruction by effector immune cells2. These neopeptides are presented 
on the surface of cancer cells generally bound by HLA-I molecules, and are subsequently 
recognized by T cells which can potentially induce an anticancer immune response3. 
Allelic HLA-I variation shapes the efficacy of antitumor immunity in a complex manner. 
HLA-I homozygosity, certain HLA-I supertypes  and germline HLA-I evolutionary 
divergence (HED) are associated with an altered overall survival in patients receiving 
immunotherapy4,5. Additionally, HLA-I genotype shapes the mutational landscape of 
tumors: common missense mutations are generally bound weaker by HLA molecules6 and 
lung cancer cells frequently lose one (or both) of their HLA-I alleles, resulting in immune 
escape of cancer cells7. 
An important feature of HLA-I alleles that has received little attention in cancer immunity 
is peptide binding promiscuity. There is a substantial variation in the size of the bound 
and presented peptide repertoire across HLA-I alleles8–10. Certain HLA- I alleles are 
capable of binding an exceptionally large set of peptide segments. For instance, a 
bioinformatics analysis has revealed over 16-fold variation in the number of peptides 
bound by common HLA-I alleles from a wide-range of dengue virus–derived peptides10. 
Similarly, the binding capacity of HLA-B molecules to a large set of self-peptides varies 
extensively, and influences the native repertoire of T-cell clones developing in the 
thymus11. Previous studies suggest that HLA class I and II peptide binding promiscuity 
has been positively selected during the evolutionary diversification of human 
populations, as they provide an enhanced capacity to withstand high pathogen 
diversity8,9. 
In this work, we study the impact of peptide-binding repertoire of HLA-I alleles on cancer 
immune checkpoint inhibitor (ICI) therapy. ICIs target inhibitory receptors on T cells and 
thereby stimulate antitumour immunity12. However, only a subset of patients responds 
adequately to ICI based immunotherapies. Therefore, understanding the immunological 
mechanisms underlying therapeutic success is of paramount importance. We found that 
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cancer patients carrying HLA-I alleles with promiscuous peptide binding are 
characterized by significantly worse prognosis after ICI immunotherapy. This trend can 
be explained by a reduced capacity of highly promiscuous HLA-I variants to discriminate 
tumour neopeptides from self-peptides. As a consequence, cancer samples from patients 
with promiscuous HLA-I alleles display signatures of an immunosuppressive tumour 
microenvironment with prominent T-cell dysfunction. Taken together, these results 
indicate that HLA-I alleles with low peptide binding specificities represent a genetic 
barrier to effective cancer immunotherapy. 
Results  
Peptide binding specificity of HLA-I alleles  
Our first aim was to estimate the peptide-binding specificity of individual HLA-I alleles by 
collecting peptide–HLA-I interactions validated experimentally in vitro (see Methods). In 
total, we analyzed over 250000 peptide-HLA interactions covering 67 HLA-A, -B or -C 
alleles with appropriate in vitro data. These alleles are present at detectable frequencies 
and cover a large fraction of individuals in numerous human populations. Importantly, all 
HLA-A and HLA-B alleles of a well-established reference set with maximal population 
coverage13 were included in our analysis. 
An established protocol was used to identify the amino acid composition of the peptides 
bound by the peptide binding domain of each HLA-I allele (see Methods). Using these data, 
we calculated peptide binding promiscuity (Pr), an index that estimates the sequence 
diversity of the peptides presented by each allele (see Methods). Alleles with high Pr are 
capable of binding a wide-variety of peptides and can be explained with diverse peptide 
motifs (Supplementary Fig 1). Bound peptides are enriched in either hydrophobic, basic 
amino acids or in tyrosine at anchor positions 2 and/or 9 (Supplementary Fig 1). At the 
same time, the selectivity at these and other positions are low compared to other alleles 
(Supplementary Fig 1). 
We found a substantial variation in Pr across common HLA-A, HLA-B and HLA-C alleles 
(Figure 1A). The reliability of the calculated Pr values was first confirmed by analyzing 
the data of two large-scale immunopeptidomics studies14,15. These studies identified 
naturally eluted self-peptides from the surface of HLA-I monoallelic cell lines, and include 
peptide data for 10 HLA-A, 6 HLA-B and 15 HLA-C alleles. We found a strong positive 
correlation between Pr 
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Figure 1. Basic properties of HLA-I allelic promiscuity. A) The promiscuity (Pr) values for the 67 HLA class I alleles used in our study are shown in increasing 
order. B) Amino acid diversity of self-peptides presented by the given allele on monoallelic cell lines is shown as the function of allele promiscuity. Alleles with higher 
promiscuity present more diverse peptide sequences C) The fraction of immunogenic neoepitopes bound by the given allele is shown as the function of allele 
promiscuity. Binding was determined in vitro with ProImmune REVEAL assays. D-F) The predicted fraction of bound neopeptides (D), human-peptides identified in 
immunopeptidomic studies (E) and viral peptides (F) is shown as the function of HLA promiscuity. On plots B to E, Spearman’s coefficient is shown with the level of 
significance and dashed lines indicate smooth curve fitted using cubic smoothing spline method in R (see Methods). 
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 
The copyright holder for this preprintthis version posted June 26, 2020. ; https://doi.org/10.1101/2020.06.25.170472doi: bioRxiv preprint 
and peptidome diversity on the cell surface (Figure 1B). The correlation remained when data of the 
two studies were analyzed separately (Supplementary Fig 2). 
Additionally, the in vitro binding affinities of 11 representative HLA-I alleles to 29 tumour 
neoepitopes were measured with ProImmune REVEAL HLA-peptide binding assays. These alleles are 
widespread, and are consequently part of a small set of reference HLA variants that allows maximal 
covering of human populations13. The selected peptides were collected from the TANTIGEN 
database16. These peptides elicit a cytotoxic immune response (Supplementary Data), and display 
limited or no overlap in sequence (see Methods). The analysis revealed a substantial variation in the 
binding affinities to different peptides (Supplementary Data). Reassuringly, there was a strong 
positive correlation between Pr and the fraction of neopeptides bound by a given allele (Figure 1C, 
Spearman’s rho: 0.86, P = 7*10-4). 
To confirm the results reported above, the binding specificities of HLA-I alleles against established 
sets of 1929 cancer peptides (Supplementary Data) and 9544 viral peptides derived from diverse 
pathogens (Supplementary Data) were calculated using the NetMHCpan-4.0 algorithm17. 
Additionally, it was also tested whether Pr is associated with the diversity of human self-
immunopeptidome, using a set of 212,090 peptides identified in 25 immunopeptidomics studies 
(Supplementary Data). It was found that HLA-I variants with high Pr present a larger diversity of 
neopeptides, human self-peptides and viral peptides (Figure 1, D to F, Supplementary Data). These 
associations remained significant in multivariate linear regression models including the HLA-I locus 
as a categorical predictor variable (Supplementary Table 1). Together, these results indicate that 
HLA-I peptide binding promiscuity shapes the diversity of presented tumour, human self and viral 
immunopeptidome as well. They also verify that Pr is a suitable index for estimating the diversity of 
peptides presented by HLA-I alleles.  
As the stability of peptide-HLA complexes is essential for an effective antigen presentation18, we 
finally evaluated whether promiscuous HLA-I alleles have an altered capacity to form stable protein 
complexes with neoepitopes. The assembly and dissociation rates of 66 representative neoepitope-
HLA-I complexes were measured in vitro using ProImmune Complete rate assays (see Methods). On 
average, the assembly of the complexes tends to be faster and the resulting complexes are more 
stable with high Pr HLA-I molecules (Figure 2A to D). These results were further supported by the 
computational analysis of HLA-peptide complex stability, involving 67 HLA alleles and 
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Figure 2. High allele promiscuity is associated with more stable peptide-HLA complexes. A) In vitro measured 
half-time of complex assembly for 66 allele-neoepitope pairs. Alleles were stratified into low and high promiscuity 
groups based on median. B) Peptide-HLA complexes of promiscuous HLA variants are more stable. The Y axis shows 
complex half-life in hours. C) Promiscuous alleles are 4.2-times more likely to form complexes with an assembly half-
time less than 24 hours and D) 6.7-times more likely to form especially stable complexes with a half-life longer than 
24 hours. For panel C and D, the P-values for Fisher’s exact tests are indicated. E) Predicted half-life of neopeptide-
HLA complexes, using the NetMHCstabpan algorithm23. Complexes were identified by predicting the binding affinity 
of 1929 neopeptides to 67 HLA-I alleles (see Figure 1D and Methods). Alleles were stratified into low and high 
promiscuity groups using the same cutoff as for panel A and B. On panels A, B and E, the P-value for Wilcoxon’s rank-
sum tests are indicated. Violin plots show the density function of values indicated on Y axes and horizontal lines 
indicate the median value in each group.
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1929 neopeptides (Figure 2E, see Methods for details). We conclude that, in contrast to 
other proteins19, there is no evidence for a negative trade-off between binding 
multispecificity and complex stability in case of HLA-I molecules. 
High level of HLA-I promiscuity yields worse prognosis 
To investigate the impact of Pr on cancer immunotherapy, we focused on previously 
published cohorts of cancer patients treated with ICI4,20–22. We collected data on 
melanoma patients receiving anti-CTLA-4 therapy4,20,21 (N = 164), NSCLC patients treated 
with anti-PD-1 therapy22 (N = 74), and melanoma patients treated with anti-PD-1/anti-
PDL-1 therapy4 (N = 89). The HLA genotype of patients in these three cohorts were 
determined previously4. For each patient, we calculated genotype Pr, as the mean of six 
HLA-A, HLA-B and HLA-C allelic Pr values, under the assumption that that each locus 
contributes to the presentation of neopeptides. There was a substantial variation in 
genotype Pr across patients in the examined cohorts (Supplementary Fig. 3). 
We next examined how genotype Pr affects overall survival probability in response to ICI 
therapy. Patients were classified into high, medium and low genotype Pr, based on the top 
and bottom quartiles as cutoffs. High genotype Pr was found to be associated with 
reduced overall survival in all three cohorts. (Figure 3A to C). For example, survival rates 
of high genotype Pr melanoma patients treated with CTLA-4 inhibitors were 54% lower 
than that of patients in the low Pr group, while the high genotype Pr group of NSCLC 
patients treated with PD-1 inhibitors were 57% less likely to survive than individuals in 
the low Pr group. 
HLA-I promiscuity is a major determinant of patient survival 
The relationship between the level of HLA-I promiscuity and survival remained 
significant or became even stronger when patients homozygous on any of the HLA-I loci 
were excluded from the analysis (Figure 3, D to F). Similarly, the association remained 
significant when the analysis was iteratively repeated by excluding individuals carrying 
specific HLA alleles (Supplementary Table 2). Hence, the impact of HLA promiscuity on 
patient survival cannot be explained by a single, highly prevalent allele with peculiar 
peptide binding properties. 
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Based on the structural properties of the peptide binding regions, genetically related HLA-
I alleles were previously classified into 12 supertypes that cover the majority of common 
HLA-A and HLA-B alleles24. Melanoma patients carrying HLA-B alleles belonging to the 
B44 superfamily were reported to have significantly better survival after ICI treatment, 
but the reasons have remained unclear4. Notably, the association between patient 
survival and B44 supertype is mainly due to specific HLA-B alleles, such as B*18:01, 
B*44:02, B*44:03, B*44:05, B*50:01. The four B44 alleles included in our analysis have 
particularly low Pr compared to other alleles (Supplementary Fig 4). 
Tumor mutation burden25 (TMB), HLA-I heterozygosity4 and HLA-I evolutionary 
divergence5 (HED) have previously been suggested as the determinants of response to ICI 
therapy. These features are expected to increase the diversity of neopeptides that can be 
presented on the surface of tumour cells12. Genotype Pr showed no statistically significant 
relationship with HED and HLA-I heterozygosity (Supplementary Fig 5). Moreover, the 
negative association between genotype Pr and patient survival remained highly 
significant in a multiple Cox-regression model after controlling for these features (Figure 
3G). In particular, TMB and genotype Pr appeared to be the strongest determinants, while 
HED and HLA-I heterozygosity had no significant effect on survival in this model. This is 
in line with a prior work showing no association between HLA class I heterozygosity and 
survival of NSCLC patients receiving immunotherapy26. Furthermore, the impact of Pr on 
patient survival remained after controlling for the effect of specific HLA-B supertypes B44 
and B62, which have previously been associated with survival outcome4 (Figure 3G). 
We next evaluated whether the low Pr of each HLA locus contributes to improved 
survival. For this purpose, the mean Pr was calculated for HLA-A, HLA-B and HLA-C loci 
individually and also for the combinations thereof. The promiscuity level of HLA-B was 
predictive of survival outcome, but the negative association between genotype Pr and 
patient survival becomes even stronger by inclusion of HLA-A and HLA-C into univariate 
Cox models (Supplementary Table 3). The prominent effect of HLA-B on patient survival 
might be explained by the relatively high abundance of this molecule on the cell surface 
relative to that of HLA-A and HLA-C4,27. Finally, genomic analysis of cancer mutations in 
165 patients revealed no significant association between genotype Pr and the frequency 
of loss of heterozygosity events at any of the HLA-I loci (Wilcoxon’s rank-sum test 
P = 0.64). 
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Figure 3. High allele promiscuity and survival rate of melanoma patients receiving anti-CTLA-4 therapy 
(A, D), NSCLC patients receiving anti-PD1 therapy (B, E) and melanoma patients receiving anti-PD1/anti-
PD-L1 therapy (C, F). Patients were classified into two (B-C and E-F) or three (A and D) groups based on 
quartiles of genotype Pr. Promiscuity was cut at the upper quartile for B and E and at the lower quartile for C and 
F. Log-rank test P-values are shown. Between-group differences were also tested for trend in case of A and B (see 
Methods). The analysis was carried out for all patients (A-C) or only for patients fully heterozygous at the HLA-I 
loci (D-F). G) The effect of genotype Pr on survival remained highly significant in a multiple Cox regression model 
including mutation burden and other HLA-associated features as covariates. The model involved all patients from 
panel A to C. Genotype Pr, mutation burden and mean HED were treated as continuous variables.
G 
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Reduced discrimination capacity of self and mutated peptides by promiscuous 
HLA-I molecules 
We next asked whether the presentation of more diverse peptides by promiscuous HLA-
I molecules results in a reduced capacity to differentiate between human self-peptides 
and their mutated counterparts (neopeptides). For this purpose, we calculated the 
differential agretopicity index28 (DAI), which is a broad indicator of neopeptide 
dissimilarity from self and thereby a feature of immunogenicity28. DAI estimates the 
difference between the predicted affinity for the mutant peptide and the corresponding 
non-mutated homologous peptide pair28. To gain insight into the capacity of each HLA-I 
molecule to discriminate between self and tumour peptides, we employed a set of 589 
experimentally verified tumour neopeptides (see Methods). For each HLA-I variant, we 
calculated the median DAI for neopeptides bound by the given HLA-I allele (see Methods). 
A strong negative association was found between median DAI and the level of promiscuity 
for HLA-A and HLA-B alleles, but not for HLA-C alleles (Figure 4, A to C). 
An elevated level of HLA-I promiscuity has been suggested to be favorable in terms of 
eliciting an immune response against diverse viral infections8,9. Therefore, it is important 
to establish whether the results above are specific to tumour neopeptides or they also 
hold for virus-derived epitopes. We analyzed a previously compiled set of 1030 viral 
epitopes with established positive T-cell assays29. To calculate DAI for viral peptides, each 
peptide was aligned against the non-mutated human proteome and the closest human hit 
was retrieved to calculate relative peptide-HLA-I binding affinities, as described earlier30. 
The analysis revealed no significant association between median DAI of bound viral 
peptides and allelic HLA-I promiscuity level (Figure 4, D to F). As most studied viral 
peptides displayed only a limited sequence similarity to the human proteome (Figure 4G), 
DAI values for viral peptides were much higher than for neopeptides (Figure 4H). 
Consequently, even HLA molecules with a low peptide binding specificity could be able to 
discriminate between viral and human-self peptides. 
It has been previously suggested that tumours carrying high DAI neopeptides are more 
susceptible to immune recognition and hence should be responsive to ICI therapy28,31–33. 
Therefore, a next important question is how HLA-I promiscuity shapes the abundance of 
potentially immunogenic, high DAI neopeptides in cancer patients. For this purpose, we 
analyzed the cancer genomes of 139 melanoma patients treated with CTLA-4 
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Figure 4. HLA-I allelic promiscuity and differentiation capacity between neopeptides and the 
corresponding non-mutated peptides. Relationship between the promiscuity of A) HLA-A, B) HLA-B and C) 
HLA-C alleles and median DAI for bound tumour neopeptides. Higher HLA-A and HLA-B promiscuity is associated 
with a lower median DAI value, while there is no significant relationship between the two variables in case of 
HLA-C. There is no statistically significant relationship between promiscuity of D) HLA-A, E) HLA-B and F) HLA-
C alleles and the median DAI calculated for bound viral peptides. G) The maximum BLOSUM62 sequence 
similarity of neopeptides and viral peptides to the non-mutated human proteome. H) DAI values for HLA-bound 
viral peptides are much higher than for neopeptides. I) Bound neopeptides in melanoma samples with 
promiscuous HLA alleles have a lower median DAI. J) The same patients were stratified into low, medium and 
high genotype DAI groups based on the 1st and 3rd quartiles of all values. A higher median DAI was associated 
with better survival. Log-rank test P-value is shown. Between-group differences were also tested for trend (see 
Methods). Spearman’s rho and the associated P-values are shown on figures A to F and I. Wilcoxon’s rank sum 
test P-values are shown on figures G and H. On figures A to F and I, dashed lines indicate a smooth curve fitted 
using cubic smoothing spline method in R (see Methods). On boxplots, horizontal lines indicate median, boxes 
indicate the interquartile range (IQR), vertical lines indicate 1st quartile - 1.5*IQR and 3rd quartile + 1.5*IQR.
J 
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inhibitors20,21. From the detected set of non-synonymous mutations in each cancer 
sample, we determined the complete set of neopeptides bound to at least one of the HLA-
I alleles in the corresponding patient (see Methods). The median DAI for neopeptides 
showed a significant negative association with genotype Pr (Figure 4I) indicating that that 
the immunogenicity of neopeptides is contingent upon HLA-I promiscuity level. As 
earlier28,30, we also found that higher median DAI is associated positively with patient 
survival (Figure 4J). These results do not simply reflect differences in the set of cancer 
mutations across patients. For each genotype, DAI was calculated as the mean of allele-
specific values determined on a fixed set of 589 experimentally confirmed neopeptides, 
and the positive association between DAI and survival was found to remain 
(Supplementary Fig 6). Together, these results indicate that patients who carry 
promiscuous HLA-I alleles have a reduced capacity to differentiate between self-peptides 
and the corresponding mutant tumour neopeptides with implications on patient 
survival28. 
HLA-I promiscuity and T-cell tolerance 
Immunogenic neopeptides need to have a strong binding affinity to HLA-I/T-cell receptor 
complexes. However, when their non-mutated counterparts are also presented by HLA 
molecules, the corresponding CD8+ T-cells reactive to the neopeptides are expected to be 
removed by central tolerance in the thymus or are inhibited by peripheral tolerance28,33. 
Here we focus on the impact of HLA-I promiscuity on peripheral tolerance, a mechanism 
that ensures that self-reactive T and B cells which have not been eliminated by central 
tolerance in the thymus do not recognize self-peptides as foreign ones and initiate auto-
immune reactions34. However, elevated level of T-cell tolerance in the tumour 
microenvironment contributes to uncontrolled tumor growth35,36. We hypothesized that 
due to the reduced discrimination capacity of self and tumour peptides in patients 
carrying high Pr HLA-I alleles, regulation of T-cells in the tumour microenvironment is 
shifted from activation to tolerance, yielding reduced capacity to eliminate cancer cells 
upon ICI therapy. 
To identify molecular and cellular signatures of T-cell tolerance in cancer samples, we 
focused on datasets from melanoma patients treated with the anti-CTLA4 antibody 
ipilimumab20. A unique aspect of this dataset is that it combines information on the 
transcriptome for a sufficient number of pre-treatment cancer samples with HLA-
genotype, and disease progression of each patient.  
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We first performed a gene set enrichment analysis comparing patients with high and low 
genotype Pr. Most notably, the genes involved in the positive regulation of T-cell tolerance 
induction, type 2 immune response, extracellular matrix secretion and macrophage 
induction were found to be up-regulated in high Pr cancer samples (Figure 5A). Similarly, 
the genes associated with the negative regulation of T helper 1 cell mediated immune 
response and CD4+ alpha beta T-cell differentiation were expressed at higher levels in 
high Pr samples (Figure 5A). These cellular processes are linked to the induction of an 
immunosuppressive tumor microenviroment36,37. Specifically, macrophages inhibit 
effector immune responses and stimulate angiogenesis38. Additionally, they skew type 1 
immune response (mediated by T helper 1 cells) towards type 2, which is less effective 
against cancer cells37,38. Remodeling of the extracellular matrix is essential for immune 
suppression and cancer progression39,40. Finally, the lower level of CD4+ T-cell 
differentiation and T-cell tolerance induction prohibit effective tumor destruction35,36. 
Next, by applying state-of-the-art immune deconvolution methods and recommendations 
of prior benchmark studies41, we assessed the immune cell composition in these tumor 
samples41. The analysis revealed an overrepresentation of cells associated with 
immunosuppression in the tumour samples derived from patients with high genotype Pr 
(Figure 5B), including regulatory T-cells (Tregs), cancer associated fibroblasts, 
macrophages/monocytes and endothelial cells. Tregs and macrophages produce 
immunosuppressive mediators, such as TGF-β, which downregulates effector immune 
functions, and induce the development and survival of regulatory T-cells42. As expected, 
cancer samples from high Pr patients displayed increased expression of TGFB1 encoding 
TGF-β (Figure 5C). This is significant, as elevated TGF-β expression is associated with the 
promotion of tumorigenesis43. Similarly, FOXP3 gene - that encodes a master regulator 
protein involved in the development and function of Tregs – was also highly expressed in 
these samples35 (Figure 5C). 
T-cell co-stimulation is an essential step in developing T-cell tolerance or function35. 
Negative costimulatory molecules inhibit T-cell activation at immune checkpoints leading 
to T-cell tolerance35. Consequently, the inhibitory immune checkpoint receptor PD-1, as 
well as the and co-inhibitory receptors TIGIT and TIM3 have established roles in 
promoting tumor immune evasion44,45. Genes encoding these three molecules displayed 
significantly elevated expression in cancer samples with high Pr (Figure 5D). It is well-
known that TIM3 is especially abundant in FOXP3 expressing Treg cells and 
macrophages46. 
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Figure 5. Association of high HLA genotype promiscuity with an immunosuppressive cancer microenvironment. Patiens were stratified into low and high 
genotype Pr groups using the median as a cutoff. A) Results of gene set enrichment analysis. Gene sets enriched in high genotype Pr samples with a P < 0.001 and FDR 
< 0.1 are shown. Terms are classified into three main categories. Terms associated with the development of an immunosuppressive tumor microenvironment are 
highlighted in bold. B) Results of immune deconvolution analysis. Boxplots show approximated cell abundance in samples with low and high genotype Pr is shown 
on boxplots. C) Expression of genes encoding the cytokine TGF-β and the transcription factor FOXP3, molecules associated with T-cell tolerance. D) Expression levels 
of genes encoding checkpoint molecules are indicated on the figure. E) Expression of genes encoding master regulators associated with T cell dysfunction. F) High 
genotype Pr is associated with and elevated T-cell dysfunction score calculated by the TIDE algorithm. Spearman’s rho and correlation P-values are indicated. Dashed 
red line indicates linear regression line. On panels B to E, P-values for Wilcoxon’s rank sum tests are shown. On boxplots, horizontal lines indicate median, boxes 
indicate the interquartile range, vertical lines indicate 1st quartile - 1.5*IQR and 3rd quartile + 1.5*IQR. 
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Irreversible dysfunction of T-cells is a common cause of non-responsiveness to immune checkpoint 
blockade therapy47, and is linked to the formation of an immunosuppressive tumor 
microenvironment36. Therefore, we next asked whether high Pr HLA-I alleles are associated with 
signatures of T-cell dysfunction. Remarkably, we found that cancer samples with high Pr display high 
expresson levels of genes encoding TOX, TOX2, T-bet and BLIMP1 (Figure 5E). These transcription 
factors are critical for the progression and the maintenance of T-cell dysfunction48,49. To investigate 
T-cell dysfunction signatures in cancer samples more systematically, we employed the Tumor 
Immune Dysfunction and Exclusion (TIDE) method47. TIDE is a recently developed computational 
tool providing genome-wide scores of T-cell dysfunction and T-cell exclusion signatures for each 
tumor and can reliably predict ICI response. Importantly, the dysfunction score describes the level of 
late-stage, irreversible dysfunction of T-cells as reported by the authors47. We found a positive 
correlation between genotype Pr and T-cell dysfunction score (Figure 5F, Spearman’s rho: 0.4, P = 
0.03), but not between genotype Pr and T-cell exclusion score (Spearman’s rho= -0.1, P = 0.6). This 
suggests that HLA-I promiscuity level does not affect T-cell infiltration directly, but rather it shapes 
the functioning of T-cells in the tumour microenvironment. Importantly, other clinically relevant 
HLA-I associated features, such as HLA-I heterozygosity, germ-line HLA-I evolutionary divergence 
and specific HLA-I supertypes showed no association with T-cell dysfunction score (Supplementary 
Fig 7).  
Taken together, these results indicate that cancer samples carrying highly promiscuous HLA-I alleles 
tend to display signatures of immune-suppressive tumour microenvironment and T-cell dysfunction 
resulting in resistance to ICI therapy.  
Discussion 
HLA-I genes encode a critical component of the adaptive immune system. The human genome 
contains six primary allelic variants encoded by HLA-A, HLB-B and HLA-C. Together, these alleles 
define the set of individual peptides presented to T-cells1. The resulting peptide repertoire – or 
immunopeptidome – substantially differs across individuals, due to the remarkable sequence 
variation in the peptide binding region of these genes. As a consequence, each allele presents a 
distinct, and only partially overlapping set of peptides. Moreover, HLA variants differ by orders of 
magnitude in the breadth of peptides they can bind8,9. HLA-I alleles with promiscuous peptide 
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binding may be favorable in pathogen-rich environments8, but their role in anticancer immunity has 
remained unestablished. 
To investigate this issue, we first developed a computational tool to systematically explore the 
sequence diversity of the peptide set presented by different HLA-I molecules, and found that high 
HLA-I promiscuity is associated with enhanced diversity of tumour, viral and self-
immunopeptidomes as well (Figure 1 B, D to F). Next, we showed that melanoma and NSCLC cancer 
patients carrying HLA-I alleles with high Pr display significantly worse prognosis after ICI 
immunotherapy (Figure 3). This pattern is surprising, as the breadth of bound peptides by HLA-I 
molecules is expected to underlie a successful immunologic control of cancer. Therefore, we next 
aimed to establish the deleterious side-effects of elevated HLA-I promiscuity level on anti-cancer 
immunity. 
The stability of the peptide–HLA-I complex is a strong predictor of antigen immunogenicity18. In 
contrast to expectations, promiscuous HLA variants tend to form more stable HLA-peptide 
complexes (Figure 2). This finding has important immunological implications and should be further 
investigated in future research. On the other hand, we found a strong negative association between 
the level of promiscuity and the differential binding affinity of mutated neopeptides (Figure 4). This 
suggests that HLA variants with promiscuous peptide binding have a reduced capacity to 
discriminate self-peptides from mutated tumour peptides. 
We hypothesized that as a consequence, regulation of T-cells in the tumour microenvironment is 
shifted from activation to tolerance, yielding reduced a capacity to eliminate cancer cells upon ICI 
therapy. In agreement with expectation, cancer samples from melanoma patients carrying 
promiscuous HLA-I alleles displayed molecular and cellular signatures of peripheral T-cell tolerance 
and an immunosuppressive tumour microenvironment (Figure 5). These signatures include 
increased prevalence of regulatory T-cells and other immunosuppressive cells in the tumour 
microenvironment, elevated expression of immune checkpoint inhibitory receptors (PD-1), 
suppressive soluble mediators (TGF-β) and master control genes involved in regulatory T-cell 
development and maintenance (e.g. FOXP3). Future work should elucidate the exact molecular 
pathways underlying these patterns. This research will require a series of HLA transgenic mice 
studies on the role of promiscuity in T-cell initiated immune response. The impact of HLA-I 
promiscuity level on central tolerance and potential depletion of T-cells in the repertoire in healthy 
individuals also remains to be elucidated50.  
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In sum, high peptide binding promiscuity could be a common feature of genetically diverse HLA-I 
variants associated with reduced survival upon ICI therapy. Therefore, this metric could potentially 
be used for future clinical trials to identify genetic variables that affect anti-tumor immunity. 
Importantly, HLA promiscuity is conceptually different from and statistically independent of other, 
previously identified determinants driving response and adverse effects of ICI immunotherapy4,5,12 
(Supplementary Fig 5). 
Our work has several important implications for future studies. First, HLA class II genotype is known 
to drive anti-tumor responses and tumour evolution in general51,52. Therefore, it is important to 
establish how the functional diversity of HLA-II molecules shapes the efficacy of ICI immunotherapy. 
Second, while the presentation of a broad range of viral peptides by promiscuous HLA-I alleles could 
be favorable in terms of acute viral infections8,9, our work indicates that such alleles impede anti-
tumour immunity. In other words, Pr could underlie a negative trade-off between antitumour 
immunity and the genetic susceptibility to viral infections. Why is it so? As viral peptides tend to 
display limited sequence similarity to the human proteome30,53 (Figure 4G), the limited 
discrimination capacity between self and non-self-peptides by promiscuous HLA alleles may be less 
of an issue in the case of antiviral immune responses (Figure 4H). Consistent with this hypothesis, 
we found no correlation between the level of HLA-I promiscuity and differential binding affinity of 
viral epitopes and self-peptides across the non-mutated human proteome (Figure 4, D to F). 
Therefore, promiscuous HLA-I molecules present a wider-range of viral epitopes (Figure 1F) without 
paying the cost of reduced discrimination between self and virus derived peptides. Third, and on a 
related note, promiscuous HLA-A and HLA-B variants are especially wide-spread in South-East Asia, 
possibly as a result of selection to withstand high pathogen load8. This pattern raises the possibility 
that there are geographical differences in the genetic make-up shaping the efficacy of cancer 
immunotherapy and anti-tumour immunity in general. Finally, prior studies suggested that 
neoantigen immunogenicity and quality, and not simply neoantigen quantity that determine patient 
survival54. Our work indicates that HLA-I peptide binding promiscuity shapes neoantigen 
immunogenicity with implications on the design of neoantigen vaccines55. 
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Methods 
Calculating peptide binding specificity  
Data on peptide-HLA class I interactions and corresponding T-cell activation assays were 
downloaded from The Immune Epitope Database1 (IEDB), as of 17th January 2019. Only peptides with 
lengths between 8 to 12 standard amino acids, and with positive MHC binding and/or T-cell 
activation assays were considered further. To ensure reliable estimates on peptide binding 
promiscuity, only HLA-I alleles with data on the binding of at least 400 different peptides were 
analyzed further. This procedure resulted in a total of 253,147 peptide-HLA I interactions across 21 
HLA-A, 31 HLA-B, and 15 HLA-C alleles. HLA-I allelic promiscuity was calculated as follows. Peptides 
were classified into discrete peptide sets according to their amino acid lengths and each set was 
analyzed separately. At each amino acid position, the amino acid frequency distribution in the 
peptide set was compared with the amino acid frequency distribution in the complete human 
proteome (downloaded from UniProt2), using Kullback-Leibler (KL) divergence. KL divergence is a 
standard metric regularly used to measure the distance between two discrete probability 
distributions (P and Q) and is calculated as follows: 






where P(x,y) denotes the frequency of amino acid x  in the peptide set at amino acid position y, while 
Q(x) denotes the frequency of the same amino acid in the complete human proteome (𝜒 is the set of 
20 amino acids). Position-specific DKL(y) values were calculated by the Rtreemix R library3. Finally, 
position specific DKL(y) values were averaged across the full peptide length and for each peptide set, 
yielding 𝐷𝐾𝐿̅̅ ̅̅ ̅.. The more selective the binding of HLA-I allele is at a given position the higher the 
deviation is between the two distributions, resulting in higher 𝐷𝐾𝐿̅̅ ̅̅ ̅ . To control for any potential 
sample size associated biases, the raw 𝐷𝐾𝐿̅̅ ̅̅ ̅ values were normalized by subtracting 𝐷𝐾𝐿̅̅ ̅̅ ̅ (rand). 𝐷𝐾𝐿̅̅ ̅̅ ̅ 
(rand) is the average of 𝐷𝐾𝐿̅̅ ̅̅ ̅ values based on the same number of randomly selected peptides with 
the same length in the human proteome iterated 1000 times. The normalized 𝐷𝐾𝐿̅̅ ̅̅ ̅ values show no 
significant correlation with the number of input peptide sequences (Spearman’s rho: -0.08, P = 0.23). 
HLA allelic promiscuity (Pr) is defined as the reciprocal value of normalized 𝐷𝐾𝐿̅̅ ̅̅ ̅, i.e. Pr = 1/ 𝐷𝐾𝐿̅̅ ̅̅ ̅. Pr 
values do not change significantly when using Q(x) derived from the proteomes of bacterial or viral 
species instead of the complete human proteome (Supplementary Fig 8C and D). Computer 
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simulations also showed that Pr can be reliably inferred using the above defined threshold of peptide 
number per HLA allele (Supplementary Fig 8A and B). Of note, Kullback-Leibler divergence, which 
measures the discrepancy between two probability distributions is conceptually related to the 
Shannon entropy index4. As expected, the Pr values based on Shannon entropy index and Kullback-
Leibler divergence show strong positive correlation with each other (Spearman’s rho: 0.86, P < 
2.2*10-16). 
Experimental analysis of HLA-I neoepitope binding affinity  
HLA-I peptide neoepitopes with established roles in mediating antitumor immune responses were 
collected from the TANTIGEN database5 (Supplementary Data). Epitopes with over 50% sequence 
identity were excluded using an iterative method6, resulting in 29 peptide neoepitopes. Each peptide 
was synthesized and their binding affinity towards a pre-selected set of 11 HLA-I variants was tested 
using the in vitro HLA class I Reveal binding assay (ProImmune Ltd., Oxford, UK). The binding assay 
determines the capability of each candidate peptide to bind to one or more HLA Class I alleles by 
assessing its ability to stabilize the HLA-peptide complex. For each allele, the binding of the tested 
peptides is scored relative to that of a corresponding high affinity T cell epitope. 
Experimental analysis of peptide-HLA complex assembly and stability 
All peptide-HLA-I pairs with positive outcome of the HLA class I Reveal binding assay were studied 
further. The assembly and stability of 66 putative peptide-HLA complexes were measured using 
Complete Rate Assays (ProImmune Ltd., Oxford, UK). The fraction of assembled complexes was 
measured at six different time points over 48 hours. After fitting the values to a one-phase association 
equation, the half-time needed to reach the maximum of assembled complexes was calculated and 
reported as the on-rate of the studied peptide-HLA complex. The stability of the complexes was 
measured using off-rate assays. This assay measures the fraction of denaturated complexes at 6 
different time points over 24 hours. These values were fitted to a one-phase denaturation equation 
and the half-life of complexes was calculated. 
Computational prediction of HLA binding affinity and complex stability  
Using literature information5,7–11, we compiled datasets of i) 1929 experimentally verified 
neopeptides, all of which are known to have high binding affinity to certain HLA alleles 
(Supplementary data), ii) 212,090 HLA-I-bound self-peptides identified in a range of 
immunopeptidomics studies (Supplementary data) and iii) 9544 viral peptides acquired from a 
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dataset that was published by Ogishi et al.12 Binding affinity of each peptide to the 67 HLA alleles 
were calculated by the NetMHCpan-4.0 algorithm13. The fraction of peptides bound by each HLA 
allele was determined for each dataset, using an established 500 nM affinity (IC50) cut-off for 
binding. The stability of complexes between HLA alleles and bound neopeptides was determined 
using the NetMHCstabpan-1.0 algorithm14, using the option of excluding prior information on exact 
binding affinity values (IC50). Half-life of peptide-HLA complex in hours was used as a proxy for 
peptide-HLA complex stability. 
Calculating peptidome diversity from mass spectrometry studies 
The accuracy of the Pr estimates was tested using the mass spectrometry immunopeptidomes 
derived from mono-allelic cell lines15,16. For each HLA class-I allele with appropriate peptidome data, 
sequence diversity of the identified peptides was measured by the Shannon entropy index. 
Analysis of cancer patients treated with ICI therapy 
Data on published cohorts of patients were collected who had melanoma treated with CTLA-4 
inhibitors17–19, melanoma treated with PD-1 inhibitors18 and NSCLC treated with PD-1 inhibitors20. 
Information on HLA genotype, loss of HLA heterozygosity and cancer mutation burden in these 
patients were derived from Ref 18. Genotype-level HLA promiscuity (or genotype Pr) was determined 
by calculating the mean of 𝐷𝐾𝐿̅̅ ̅̅ ̅ values across all HLA-A, B and C alleles of the patient and taking its 
reciprocal value. For patients with a single HLA-allele with no appropriate allelic Pr data, a standard 
imputation technique was involved by replacing the missing Pr with the median of that variable for 
all other cases. This protocol has the benefit of not changing the sample median for Pr, and it enlarges 
the dataset, but reassuringly, it has no impact on the association between survival and Pr (data not 
shown). Patients having at least two HLA alleles with unknown allelic Pr were excluded from the 
analysis. 
Data on HLA-I evolutionary divergence (HED) was derived from ref 21. Survminer22 and Survival23 R 
libraries were used for statistical analysis of patient survival. The effect of genotype Pr on survival 
was tested with logrank test and by the ggsurvplot function of Survminer R library22 , and the results 
were visualized by Kaplan-Meier curves. Survival curves of cohorts classified into more than two 
groups were also tested for ordered differences as implemented by the Survminer R library22. Cox 
regression models were generated using the coxph function of the Survival23 R library. The 
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proportional hazard assumption for the Cox regression model fit was tested with the cox.zph 
function. The forest plot for multivariate cox models was generated with the forestmodel24 R library. 
Calculating differential agretopicity index (DAI) 
Using literature information5,7–11, we compiled a dataset of experimentally verified neopeptides, all 
of which are known to have high binding affinity to certain HLA alleles (Supplementary data). To 
reach the best prediction accuracy with NetMHCpan-4.0 algorithm13,25, the analysis focused on nine 
amino acid long peptides. As earlier6, neopeptides with more than 50% sequence identity were 
excluded, resulting in 589 peptide neopeptides. Using an established method26, for each neopeptide, 
the peptide sequence was aligned against the non-mutated human proteome using BLAST+ 2.10.027. 
The closest hit was retrieved, and the BLOSUM62 sequence similarities were calculated using an 
established method28. 
The binding affinity of each neopeptide and the corresponding non-mutated human peptide to each 
of the 67 HLA-I alleles was calculated using NetMHCpan-4.013. For each HLA-I peptide pair, DAI 
values were calculated as earlier25. For each HLA allele, the median DAI value was calculated across 
all neo-peptides with significant binding affinity to the given HLA variant (i.e. lower than 2% 
predicted binding rank percentile by NetMHCpan-4.0). The same method was used for calculating 
DAI values for 1030 immunogenic nine amino acid long viral epitopes acquired from ref12 
(Supplementary Data). 
DAI values were also determined for neopeptides in 139 melanoma samples derived from two 
immunotherapy cohorts17,19. Genomic data on missense mutations in protein coding genes were 
acquired from cBioPortal29. The corresponding mutated proteins were identified using the reference 
human proteome (downloaded from UniProt database2, as of 9th January, 2020). Using these protein 
data, all possible 8 to 12 amino acid long mutated peptide segments were determined in each sample. 
Binding affinity and DAI values of each mutated peptide to each HLA class I allele of the patient was 
calculated as above. 
Transcriptome analysis of melanoma cancer samples  
Normalized RNA-seq expression data of cancer samples derived from anti CTLA-4-treated melanoma 
patients19 with established HLA-I genotype were downloaded from cBioPortal29. Immune 
deconvolution analysis was carried out following recommendations by Sturm and colleagues30 , and 
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using the immunedeconv R library30. As recommended30, we used the EPIC algorithm31 for 
endothelial cells and cancer associated fibroblasts, MCP-counter32 for macrophages/monocytes and 
quanTIseq33 for regulatory CD4+ T cells. Precalculated TIDE dysfunction and exclusion score values 
were acquired from TIDE server34. Gene set enrichment analysis was carried out with the GSEA 
4.0.3.35 software using 1000 permutations, weighted enrichment statistic and excluding gene sets 
with less than 5 genes. Gene sets of biological processes as reported by the Gene Ontology 
Consortium36 were included in the analysis. Gene sets enriched with P < 0.001 and FDR < 0.1 were 
treated as significant. 
Statistical analysis and visualization 
Statistical analyses and visualization were carried out using R v.3.6.337 under RStudio 1.2.5033 
environment. Smooth curves on plots were fitted with cubic smoothing spline method38. 
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Figure S1. Sequence diversity of peptides presented by HLA class I alleles. Sequence diversity was calculated based on nine amino acid-long peptides 
bound by each of the 67 investigated HLA class I alleles and visualized as sequence logos56. Alleles are ordered according to their promiscuity level.
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Figure S2. The relationship between HLA allele promiscuity and the diversity of presented peptides holds 
for two independent immunopeptidomics studies. We found a strong correlation between the promiscuity of 
alleles and sequence diversity of peptides eluted from the surface of monoallelic cell lines in studies by A) Abelin et 
al.14 and B) Di Marco et al.15 (Spearman’s rho: 0.67 and 0.56, P = 0.006 and 0.034 for panels A and B, respectively). 
Dashed red lines indicate linear regression line.  
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Figure S3. Distribution of genotype Pr in cancer immunotherapy cohorts. The density of genotype Pr is shown 
for A) all patients, B) melanoma patients treated with CTLA-4 inhibitors, C) non-small cell lung cancer (NSCLC) 
patients treated with PD1 or PDL-1 inhibitors and D) melanoma patients treated with PD1 or PDL-1 inhibitors. 
Dashed vertical lines represent the 25th and 75th percentile values.
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Figure S4. HLA alleles belonging to the B44 supergroup have low promiscuity. B44 alleles are highlighted in blue, and have significantly lower 
promiscuity than alleles not belonging to this group (Wilcoxon’s rank-sum test P: 0.049).
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Figure S5. No relationship between genotype Pr, HLA homozygosity and HED. A) No significant difference in 
genotype Pr was found between patients fully HLA heterozygous patients and ones homozygous for at least one HLA-
I locus. The P-value for Wilcoxon’s rank sum test is indicated. B) Similarly, there was no relationship between 
genotype Pr and mean HED of cancer immunotherapy patients (Spearman’s rho: -0.01, P = 0.79). Dashed red line 
indicates a smooth curve fitted using cubic smoothing spline method in R (see Methods). Patients from Fig. 3 A to C 
were included in both analyses. On boxplot, horizontal lines indicate median, boxes indicate the interquartile range 
(IQR), vertical lines indicate 1st quartile - 1.5*IQR and 3rd quartile + 1.5*IQR.  
  
.CC-BY-NC-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 
The copyright holder for this preprintthis version posted June 26, 2020. ; https://doi.org/10.1101/2020.06.25.170472doi: bioRxiv preprint 
 
Figure S6. The effect of genotype DAI on survival when determined as the average of allele-specific DAI 
values. Patients were stratified into groups using the 25th and 75th percentile of all values as cutoffs. Log-rank test 
P-value is shown. Between-group differences were also tested for trend (see Methods). Higher genotype DAI value 
was associated with better survival.  
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Figure S7. The effect of HLA-associated features on TIDE dysfunction score. A) The TIDE dysfunction score is 
shown as a function of HLA evolutionary divergence. There was no relationship between the two variables 
(Spearman’s rho: -0.01, P = 0.96). Similarly, neither HLA homozygosity (B), nor the carrier status for B44 (C) or B62 
(D) supertype alleles affected the TIDE dysfunction score. P-values indicate Wilcoxon’s rank sum test results. On plot 
A, dashed red line indicates a linear regression line. On boxplots, horizontal lines indicate median, boxes indicate the 
interquartile range (IQR), vertical lines indicate 1st quartile - 1.5*IQR and 3rd quartile + 1.5*IQR. 
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Figure S8. Promiscuity can be reliably inferred using a minimum threshold of 400 peptide sequences per 
allele. A-B) The number of identified peptide sequences for a given HLA allele is variable, which may have a 
significant effect on the calculated Kullback-Leibler (KL) divergence values. To test whether KL divergence can be 
reliably determined using a minimal peptide sequence number of 400, we first selected HLA alleles with large (more 
than 1000) number identified peptides (N = 51). After randomly selecting 400 sequences from the repertoire of each 
allele, we calculated KL divergence as explained in the Methods section. We iterated this process for 1000 times and 
compared the Pr values with those calculated using the full dataset. Panel A indicates the distribution of Spearman’s 
rho values and the P-values for correlations. B) An example plot indicating the relationship between promiscuity 
values calculated using either 400 random or all peptides bound by a given allele. C-D) The calculated promiscuity 
values are independent of the reference amino acid (AA) distribution used during calculation. The Pr values showed 
strong a correlation when calculated using C) human and viral or D) human and bacterial AA distributions as a 
reference (Spearman’s rho: 0.99, P < 2.2*10-16 for both comparisons). On plots B to D, dashed lines indicate a smooth 
curve fitted using cubic smoothing spline method in R (see Methods)  
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Dependent variable Coeff. P (var.) Adjusted R-squared F-test P-value 
Sequence diversity on cell surface 0.203 0.004 0.275 0.008 
Fraction of neopeptides bound 1.136 0.004 0.417 4.3 * 10-08 
Fraction of human peptides bound 1.205 9.6 * 10-05 0.264 5.3 * 10-05 
Fraction of viral peptides bound 0.035 0.006 0.408 6.6 * 10-08 
 
Table S1. The effect of HLA allele promiscuity on diversity and the fraction of bound peptides is independent 
of HLA loci. Results for multivariate models including allele promiscuity as continuous and HLA locus as categorical 
independent variables are shown. “P (var.)” values indicate the probability of observing a relationship between 
promiscuity and patient survival due to chance. Adjusted R-squared and F-test P-value of each model is indicated. 
Only the coefficient for allele promiscuity is shown.
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high Fisher's exact test P Fisher's exact test FDR 
Num. of patients 
when excluded 
Coeff. for 
prom. P (prom.) 
Log-rank test 
P 
A0201 0.221 0.994 3.774 1.6 * 10-14 3.6 * 10-13 175 2.405 0.025 0.030 
A0101 3.556 0.832 0.210 7.5 * 10-13 8.7 * 10-12 225 2.860 0.002 0.002 
B0801 3.541 0.675 0.164 2.1 * 10-11 1.6 * 10-10 264 2.599 0.001 0.001 
C0701 3.089 0.898 0.213 3.6 * 10-11 2.1 * 10-10 226 2.751 8.8 * 10-04 0.001 
B3501 0.173 0.996 2.032 2.5 * 10-04 0.001 285 3.126 6.7 * 10-05 8.9 * 10-05 
C0401 0.460 0.946 1.858 0.001 0.004 250 2.780 9 * 10-04 0.001 
A2402 0.912 1.479 0.305 0.001 0.004 270 2.411 0.001 0.002 
C0602 0.492 0.801 2.124 0.001 0.004 274 2.479 0.005 0.006 
C0202 0.116 1.281 1.419 0.004 0.010 295 2.015 0.008 0.009 
B4403 1.877 1.030 0.221 0.004 0.010 294 2.134 0.004 0.005 
B1501 0.386 0.910 1.918 0.008 0.017 288 2.047 0.007 0.008 
B1801 1.743 0.938 0.490 0.044 0.084 289 2.128 0.004 0.005 
C0304 0.595 0.854 1.778 0.054 0.096 288 2.098 0.006 0.007 
B4402 1.781 0.776 0.770 0.067 0.111 287 2.173 0.003 0.004 
C0702 0.566 1.181 1.137 0.084 0.129 244 2.256 0.003 0.004 
B5101 0.475 1.291 0.990 0.122 0.175 287 2.346 0.002 0.002 
C0501 1.596 0.827 0.822 0.152 0.206 280 2.205 0.003 0.004 
B0702 0.614 1.135 1.161 0.167 0.214 249 2.191 0.005 0.006 
A1101 0.595 1.266 0.904 0.271 0.328 288 2.112 0.005 0.005 
A0301 0.777 1.011 1.225 0.439 0.505 234 2.495 0.002 0.002 
C0303 0.610 1.137 1.129 0.506 0.555 295 2.249 0.003 0.003 
C1203 0.903 1.171 0.770 0.617 0.645 287 2.210 0.004 0.004 
A2601 0.951 1.062 0.925 0.972 0.972 293 2.213 0.003 0.003 
 
Table S2. The effect of HLA allele promiscuity on survival is independent of the effect of a single allele. We analyzed the enrichment of alleles in 
different promiscuity groups of the merged cohort including all patients from Figure 3A to C (N = 327). Only those alleles were included in the analysis, 
which were carried by at least 10% of the individuals. We stratified patients into low, medium and high genotype Pr groups based on the 25th and 75th rank 
percentiles of all values. Next, we determined the odds ratio (OR) for finding a given allele in each promiscuity group and calculated if the enrichment is 
significant using Fisher’s exact tests. Significant FDR-corrected P-values are highlighted in red. Alleles enriched in low or high promiscuity groups are 
highlighted in blue or red background colours, respectively. Next, we excluded individuals carrying the given allele from the cohort, and determined the 
effect of promiscuity (as a continuous variable) on survival using Cox models. The effect and statistical significance of HLA promiscuity, and the Log-rank 
test P for the model is shown in the table. P-values lower than 0.05 are highlighted in red.
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ANOVA P  
(vs. Model 1) 
1 A + B + C 2.362 9.1 * 10-04 0.001 -706.750 NA 
2 A 0.317 0.152 0.153 -711.077 < 2 * 10-16 
3 B 1.084 0.004 0.005 -708.233 < 2 * 10-16 
4 C 0.973 0.219 0.225 -711.362 < 2 * 10-16 
 
Table S3. The effect of genotype Pr on patient survival when calculated using 
individual loci. We examined four univariate Cox models containing the mean 
promiscuity of individual loci (Models 2 to 4) and all loci (Model 1) as predictors. The 
effect of variables on patient survival is shown. “P (var.)” values indicate the probability 
of observing a relationship between the predictor variable and patient survival due to 
chance. Log-rank test P-values and the log-likelihood values for individual models are also 
indicated. Significant ANOVA P-values indicate that the first model fits better than the 
examined one. NA: not applicable. P-values lower than 0.05 are highlighted in red. 
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